On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...
Add Yahoo as a preferred source to see more of our stories on Google. Illustration shows GSK (GlaxoSmithKline) logo (Reuters) -British pharmaceutical giant GSK said on Wednesday it would cap ...
Fluticasone propionate, salmeterol (as xinafoate); 45mcg/21mcg, 115mcg/21mcg, 230mcg/21mcg; per inh; metered-dose inhaler; CFC-free. Store at room temperature between 68° F and 77° F (20° C and 25° C) ...
A switch in Medicaid's formula could mean many children will go without inhalers in the coming months. The process change means drugmakers have to pay Medicaid if list prices on older products are ...
DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Advair" report has been added to ResearchAndMarkets.com's offering. Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose ...
GlaxoSmithKline is shifting its sales strategy for therapy Advair to stress increasing a treatment for chronic obstructive pulmonary disease (COPD), a new report states.Advair, a long-acting beta2 ...
This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results